SPRY — ARS PHARMACEUTICALS INC

Ownership history in PERCEPTIVE ADVISORS LLC  ·  3 quarters on record

This page tracks every 13F SEC filing in which PERCEPTIVE ADVISORS LLC reported a position in ARS PHARMACEUTICALS INC (SPRY). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.18% (2024 Q2)
Avg. % of fund
0.13%
First filed
2024 Q1
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 200,000 -667,319 -76.9% 0.06% $2.0M $10.05
2024 Q2 UNCHANGED 867,319 — 0% 0.18% $7.4M $8.51
2024 Q1 INITIATED 867,319 — — 0.15% $8.9M —
% of Fund (quarterly)    SPRY price (monthly, adj. close)

Other funds also holding SPRY

As of 2025 Q4 — sorted by position size

SR ONE CAPITAL MANAGEMENT, LP 3Y 6.62% Tyro Capital Management LLC 4.16% ORBIMED ADVISORS LLC 3Y 7Y 1.97% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.3% Casdin Capital, LLC 3Y 7Y 1.16% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.12% Lisanti Capital Growth, LLC 3Y 7Y 1.09% INVESTMENT MANAGEMENT ASSOCIATES INC /ADV 3Y 1.0% Rubric Capital Management LP 3Y 7Y 0.86% LEVIN CAPITAL STRATEGIES, L.P. 3Y 7Y 0.75%
← Back to PERCEPTIVE ADVISORS LLC Holdings